| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2 |
| P698 | PubMed publication ID | 9870876 |
| P50 | author | Paul Emery | Q19859634 |
| Michael Doherty | Q42305796 | ||
| P2093 | author name string | Pavelka K | |
| Williams B | |||
| Bresnihan B | |||
| Nuki G | |||
| Watt I | |||
| Rozman B | |||
| McCabe D | |||
| Rau R | |||
| Alvaro-Gracia JM | |||
| Domljan Z | |||
| Aitchison R | |||
| Cobby M | |||
| Musikic P | |||
| P433 | issue | 12 | |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| interleukins | Q194908 | ||
| P304 | page(s) | 2196-2204 | |
| P577 | publication date | 1998-12-01 | |
| P1433 | published in | Arthritis & Rheumatology | Q4797636 |
| P1476 | title | Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. | |
| P478 | volume | 41 |
| Q95359227 | Q95359227 |
| Q43280906 | 2-Acylaminopyridin-4-ylimidazoles as p38 MAP kinase inhibitors: Design, synthesis, and biological and metabolic evaluations |
| Q45078356 | 4-1BB-mediated immunotherapy of rheumatoid arthritis. |
| Q24805534 | A follow-up to "Anti-cytokine therapy in chronic destructive arthritis" by Wim B van den Berg |
| Q28751982 | A genome-wide in vitro bacterial-infection screen reveals human variation in the host response associated with inflammatory disease |
| Q37843041 | A mini-review: microRNA in arthritis |
| Q35554448 | A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate |
| Q35554739 | A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis. |
| Q37428436 | A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview |
| Q37609399 | A pharmacoeconomic review of adalimumab in the treatment of rheumatoid arthritis |
| Q33745289 | A role for the high-density lipoprotein receptor SR-B1 in synovial inflammation via serum amyloid-A. |
| Q34560362 | Abatacept: a costimulatory inhibitor for treatment of rheumatoid arthritis. |
| Q34822331 | Abrogation of antibody-induced arthritis in mice by a self-activating viridin prodrug and association with impaired neutrophil and endothelial cell function |
| Q34706876 | Advances in the treatment of rheumatoid arthritis: old versus new therapies |
| Q43162026 | Alpha-1-antitrypsin therapy ameliorates acute colitis and chronic murine ileitis. |
| Q43837387 | Amelioration of joint disease in a rat model of collagen-induced arthritis by M40403, a superoxide dismutase mimetic |
| Q35219001 | An expanding role for interleukin-1 blockade from gout to cancer |
| Q37019592 | An overview of cytokine interactions in atherosclerosis and implications for peripheral arterial disease. |
| Q36055449 | An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists |
| Q59136398 | Anakinra Therapy for Non-cancer Inflammatory Diseases |
| Q24241707 | Anakinra for rheumatoid arthritis |
| Q43061720 | Anakinra in the treatment of rheumatic disease |
| Q31089069 | Anakinra treatment of patients with rheumatoid arthritis |
| Q35842626 | Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis |
| Q37607078 | Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis |
| Q24805245 | Anti-cytokine therapy in chronic destructive arthritis |
| Q40861371 | Anti-interleukin-1 and anti-CD44 interventions producing significant inhibition of cartilage destruction in an in vitro model of cartilage invasion by rheumatoid arthritis synovial fibroblasts |
| Q34967541 | Anti-tumour necrosis factor alpha therapy for ankylosing spondylitis: international experience |
| Q36776959 | Anti-tumour necrosis factor therapy for severe inflammatory arthritis: two years of experience in Northern Ireland. |
| Q34452635 | Anticytokine therapy for osteoarthritis |
| Q36408155 | Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities |
| Q24795018 | Are synovial biopsies of diagnostic value? |
| Q34071312 | Arguments for interleukin 1 as a target in chronic arthritis |
| Q92436080 | Association of IL-1 gene polymorphisms with chronic rhinosinusitis with and without nasal polyp |
| Q37639837 | Attenuation of Collagen-Induced Arthritis in rat by nicotinic alpha7 receptor partial agonist GTS-21. |
| Q35551774 | Autoantibodies against interleukin 1alpha in rheumatoid arthritis: association with long term radiographic outcome. |
| Q80463745 | B-cell depletion in patients with rheumatoid arthritis refractant to multiple TNF blockers and the interleukin 1 receptor-antagonist anakinra. Good responses in an extreme negative selection |
| Q38993250 | Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. |
| Q26852235 | Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis |
| Q38510023 | Biologic monotherapy in the treatment of rheumatoid arthritis |
| Q36195284 | Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA). |
| Q35070925 | Biologic therapies for juvenile arthritis |
| Q34108783 | Biologic therapies in rheumatoid arthritis |
| Q35807230 | Biological agents for rheumatoid arthritis: targeting both physical function and structural damage |
| Q37984565 | Biological agents for the treatment of uveitis |
| Q34074934 | Biological agents: a novel approach to the therapy of rheumatoid arthritis |
| Q37290665 | Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences |
| Q30235341 | Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. |
| Q24185797 | Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis |
| Q39271088 | Biomaterial strategies for generating therapeutic immune responses |
| Q37382604 | Biomimetic strategies based on viruses and bacteria for the development of immune evasive biomaterials |
| Q78124802 | Blindedness in clinical trials of therapies for rheumatoid arthritis: comment on the article by Bresnihan et al |
| Q34822708 | Blocking interleukin-1 in rheumatic diseases |
| Q34001621 | Bone damage in rheumatoid arthritis: mechanistic insights and approaches to prevention |
| Q36995387 | Bone effects of biologic drugs in rheumatoid arthritis |
| Q37735544 | CCL3 and MMP-9 are induced by TL1A during death receptor 3 (TNFRSF25)-dependent osteoclast function and systemic bone loss |
| Q34047602 | CRISPR/Cas9 Editing of Murine Induced Pluripotent Stem Cells for Engineering Inflammation-Resistant Tissues |
| Q38814103 | Canakinumab for the treatment of TNF-receptor associated periodic syndrome |
| Q34336335 | Caspase functions in cell death and disease |
| Q89239808 | Caspase-1 and Caspase-11 Mediate Pyroptosis, Inflammation, and Control of Brucella Joint Infection |
| Q39292218 | Cell death and cytokine production induced by autoimmunogenic hydrocarbon oils |
| Q35573486 | Challenges in assessing costs of rheumatoid arthritis |
| Q35553008 | Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis |
| Q59809188 | Chloroquine Protects Human Corneal Epithelial Cells from Desiccation Stress Induced Inflammation without Altering the Autophagy Flux |
| Q41946037 | Chloroquine inhibits production of TNF-alpha, IL-1beta and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes |
| Q83324055 | Cia27 is a novel non-MHC arthritis severity locus on rat chromosome 10 syntenic to the rheumatoid arthritis 17q22-q25 locus |
| Q36013933 | Circulating levels of the chemokine CCL18 but not CXCL16 are elevated and correlate with disease activity in rheumatoid arthritis |
| Q34559795 | Clinical significance of cytokine determination in synovial fluid |
| Q34587438 | Combination cytokine therapy: the next generation of rheumatoid arthritis therapy? |
| Q74209980 | Combination therapy in rheumatoid arthritis |
| Q84569891 | Comparison of different biologic agents in patients with rheumatoid arthritis after failure of the first biologic therapy |
| Q36780936 | Comparison of the efficacy of biologic therapy for rheumatoid arthritis: can the clinical trials be accurately compared? |
| Q79119786 | Complete Freund's adjuvant promotes the increases of IFN-gamma and nitric oxide in suppressing chronic arthritis induced by pristane |
| Q35873708 | Considerations with the use of biological therapy in the treatment of rheumatoid arthritis |
| Q37609191 | Cost-effectiveness analysis of biological treatments for rheumatoid arthritis |
| Q56904375 | Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion |
| Q35602532 | Cross talk between neuroregulatory molecule and monocyte: nerve growth factor activates the inflammasome |
| Q37811988 | Cryopyrin-Associated Periodic Syndrome: An Update on Diagnosis and Treatment Response |
| Q34731287 | Current and future management approaches for rheumatoid arthritis |
| Q24804893 | Current perspectives on synovitis |
| Q28217681 | Cytokine traps: multi-component, high-affinity blockers of cytokine action |
| Q35109131 | Cytokine-based immunointervention in the treatment of autoimmune diseases |
| Q52613681 | Cytokine-induced interleukin-1 receptor antagonist protein expression in genetically engineered equine mesenchymal stem cells for osteoarthritis treatment. |
| Q34252489 | Cytokine-mediated bone destruction in rheumatoid arthritis |
| Q34830551 | Cytokines and anti-cytokine biologicals in autoimmunity: present and future |
| Q22306446 | Cytokines and cytokine profiles in human autoimmune diseases and animal models of autoimmunity |
| Q34593940 | Cytokines for surgeons |
| Q36504371 | Cytokines in idiopathic inflammatory myopathies |
| Q34993224 | Cytokines in immunotherapy of experimental uveitis |
| Q33974537 | Cytokines in rheumatoid arthritis: trials and tribulations |
| Q45256819 | Decrease in circulating endothelial cell adhesion molecule and thrombomodulin levels during oral iloprost treatment in rheumatoid arthritis patients: preliminary results |
| Q36148416 | Design of effective immunotherapy for human autoimmunity |
| Q89459346 | Development and effect of antibodies to anakinra during treatment of severe CAPS: sub-analysis of a long-term safety and efficacy study |
| Q33345449 | Development of interleukin-1 receptor antagonist mutants with enhanced antagonistic activity in vitro and improved therapeutic efficacy in collagen-induced arthritis |
| Q91934535 | Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases |
| Q40493960 | Dual biological functions of an interleukin-1 receptor antagonist-interleukin-10 fusion protein and its suppressive effects on joint inflammation |
| Q35933703 | Durability and rapidity of response to anakinra in patients with rheumatoid arthritis |
| Q35636722 | Duration of rheumatoid arthritis influences the degree of functional improvement in clinical trials |
| Q35746217 | Dynamics of early synovial cytokine expression in rodent collagen-induced arthritis : a therapeutic study using a macrophage-deactivating compound. |
| Q36026239 | Effect of the IL-1 Receptor Antagonist Kineret® on Disease Phenotype in mdx Mice |
| Q82906413 | Effectiveness of anakinra in rheumatic disease in patients naive to biological drugs or previously on TNF blocking drugs: an observational study |
| Q34963124 | Effects of anakinra on clinical and radiological outcomes in rheumatoid arthritis. |
| Q33573112 | Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project |
| Q53684926 | Efficacy and safety of interleukin-1 antagonists in rheumatoid arthritis: a systematic review and meta-analysis. |
| Q30560117 | Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data |
| Q38993229 | Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis |
| Q36062038 | Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis |
| Q38068578 | Emerging drugs for axial spondyloarthritis including ankylosing spondylitis |
| Q38738678 | Equine performance genes and the future of doping in horseracing. |
| Q35190112 | Evaluation and management of psoriatic arthritis: the role of biologic therapy |
| Q37039428 | Evaluation of Anti-Inflammatory Potential of the New Ganghwaljetongyeum on Adjuvant-Induced Inflammatory Arthritis in Rats |
| Q28082757 | Evasion of inflammasome activation by microbial pathogens |
| Q57306277 | Evidence of a pharmacogenomic response to interleukin-l receptor antagonist in rheumatoid arthritis |
| Q39788053 | Expression and function of the NALP3 inflammasome in rheumatoid synovium. |
| Q37359799 | Expression of microRNA-146 in rheumatoid arthritis synovial tissue |
| Q54791119 | Expression of the dendritic cell-associated C-type lectin DC-SIGN by inflammatory matrix metalloproteinase-producing macrophages in rheumatoid arthritis synovium and interaction with intercellular adhesion molecule 3-positive T cells. |
| Q47348590 | Extracts of Arisaema rhizomatum C.E.C. Fischer attenuate inflammatory response on collagen-induced arthritis in BALB/c mice |
| Q41581182 | Feasibility randomised multicentre, double-blind, double-dummy controlled trial of anakinra, an interleukin-1 receptor antagonist versus intramuscular methylprednisolone for acute gout attacks in patients with chronic kidney disease (ASGARD): protoc |
| Q64377367 | Gene Transfer of a Cell Cycle Modulator Exerts Anti-Inflammatory Effects in the Treatment of Arthritis |
| Q37214931 | Gene polymorphisms and pharmacogenetics in rheumatoid arthritis |
| Q35881986 | Gene targeting: roadmap to future therapies |
| Q35122176 | Gene therapy for arthritis |
| Q45875960 | Gene therapy: will it deliver for RA? |
| Q35164793 | Gene transfer as a future therapy for rheumatoid arthritis |
| Q44213356 | Gene-mediated restoration of cartilage matrix by combination insulin-like growth factor-I/interleukin-1 receptor antagonist therapy |
| Q48064243 | Generalizability of Patients With Rheumatoid Arthritis in Biologic Agent Clinical Trials. |
| Q47697061 | Genome Engineering for Personalized Arthritis Therapeutics |
| Q44353882 | Glutathione s-transferase omega 1-1 is a target of cytokine release inhibitory drugs and may be responsible for their effect on interleukin-1beta posttranslational processing |
| Q56212157 | Guidelines for the management of rheumatoid arthritis: 2002 Update |
| Q37498849 | Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis |
| Q36154364 | Have traditional DMARDs had their day? Effectiveness of parenteral gold compared to biologic agents |
| Q47844482 | High expression of myeloid-related proteins 8 and 14 characterizes an inflammatorily active but ineffective response of macrophages during leprosy. |
| Q35605628 | Human, viral or mutant human IL-10 expressed after local adenovirus-mediated gene transfer are equally effective in ameliorating disease pathology in a rabbit knee model of antigen-induced arthritis |
| Q33427482 | Hyperbaric oxygen inhibits stimulus-induced proinflammatory cytokine synthesis by human blood-derived monocyte-macrophages |
| Q36304279 | IL-1 family cytokines trigger sterile inflammatory disease |
| Q34074678 | IL-1 inhibitors: novel agents in the treatment of rheumatoid arthritis |
| Q37696955 | IL-1 pathways in inflammation and human diseases |
| Q63214372 | IL-1-Antagonisten |
| Q45337887 | IL-1-dependent, IL-1R1-independent resistance to gastrointestinal nematodes |
| Q53529589 | IL-15 exacerbates collagen-induced arthritis with an enhanced CD4+ T cell response to produce IL-17. |
| Q24796707 | IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis |
| Q77807763 | IL-18: A TH1-inducing, proinflammatory cytokine and new member of the IL-1 family |
| Q37702138 | IL-1: discoveries, controversies and future directions |
| Q34916928 | IL-1β suppresses innate IL-25 and IL-33 production and maintains helminth chronicity. |
| Q41394835 | IL-1β/HMGB1 complexes promote The PGE2 biosynthesis pathway in synovial fibroblasts |
| Q37202023 | IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion |
| Q35011144 | Identification of constitutively active interleukin 33 (IL-33) splice variant |
| Q36778450 | Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution |
| Q33760317 | Immunomodulation of autoimmune responses with monoclonal antibodies and immunoadhesins: treatment of ocular inflammatory disease in the next millennium |
| Q43273894 | Immunomodulator agent-related lymphoproliferative disorders |
| Q33709280 | Immunopharmacology: anti-inflammatory therapy targeting transcription factors |
| Q34360546 | Immunotherapy for rheumatoid arthritis |
| Q37172804 | Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry-based control group |
| Q52660383 | In vivo monitoring of activated macrophages and neutrophils in response to ischemic osteonecrosis in a mouse model. |
| Q35084908 | Infection complications associated with the use of biologic agents |
| Q28194382 | Inflammation and infection in clinical stroke |
| Q43539087 | Inflammation in dry eye associated with rheumatoid arthritis: cytokine and in vivo confocal microscopy study |
| Q28083759 | Inflammation induced loss of skeletal muscle |
| Q41457693 | Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1beta |
| Q79277558 | Inflammatory cytokines correlated with clinical outcome of temporomandibular joint irrigation in patients with chronic closed lock |
| Q34461355 | Influence of interleukin-1 receptor antagonist gene polymorphism on disease |
| Q36573901 | InforMatrix: treatment of rheumatoid arthritis using biologicals |
| Q36494210 | Inhibition of IL-1, IL-6, and TNF-alpha in immune-mediated inflammatory diseases |
| Q44198853 | Inhibition of cartilage destruction by double gene transfer of IL-1Ra and IL-10 involves the activin pathway |
| Q37924648 | Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations |
| Q24793971 | Interferon-beta for treatment of rheumatoid arthritis? |
| Q35841729 | Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury |
| Q34420855 | Interleukin 1 receptor signaling regulates DUBA expression and facilitates Toll-like receptor 9-driven antiinflammatory cytokine production |
| Q34484529 | Interleukin-1 Receptor Signaling Is Required To Overcome the Effects of Pertussis Toxin and for Efficient Infection- or Vaccination-Induced Immunity against Bordetella pertussis |
| Q35133812 | Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives |
| Q38666235 | Interleukin-1 function and role in rheumatic disease |
| Q77118254 | Interleukin-1 receptor antagonist |
| Q34452084 | Interleukin-1 receptor antagonist as therapy for inflammatory disorders |
| Q24199001 | Interleukin-1 receptor antagonist for treating periodontitis |
| Q24240691 | Interleukin-1 receptor antagonist for treating periodontitis |
| Q34297349 | Interleukin-1 receptor blockade in perinatal brain injury |
| Q42058247 | Interleukin-15 and interferon-gamma participate in the cross-talk between natural killer and monocytic cells required for tumour necrosis factor production |
| Q47632515 | Interleukin-1beta and tumor necrosis factor-alpha produce distinct, time-dependent patterns of acute arthritis in the rat knee |
| Q53853386 | Interleukin-1β, interleukin-1 receptor antagonist, and interleukin-1 soluble receptor II in temporomandibular joint synovial fluid from patients with chronic polyarthritides |
| Q34047753 | Interleukins and interleukin receptors in rheumatoid arthritis: Research, diagnostics and clinical implications |
| Q30804224 | Interpreting radiographic data in rheumatoid arthritis |
| Q40340532 | Intravenous application of omega-3 fatty acids in patients with active rheumatoid arthritis. The ORA-1 trial. An open pilot study |
| Q34626968 | Juvenile rheumatoid arthritis: therapeutic perspectives |
| Q36277831 | Kinase inhibitors: a new class of antirheumatic drugs |
| Q44068969 | Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis |
| Q37118963 | Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes |
| Q26750562 | Macrophage migration inhibitory factor: a potential therapeutic target for rheumatoid arthritis |
| Q24806949 | Macrophages in rheumatoid arthritis |
| Q36295221 | Management issues with elderly-onset rheumatoid arthritis: an update |
| Q33754764 | Matrix Metalloproteinase Gene Activation Resulting from Disordred Epigenetic Mechanisms in Rheumatoid Arthritis. |
| Q35720483 | Measurement of structural abnormalities in arthritis using radiographic images |
| Q36864025 | Mechanisms of disease: a 'DAMP' view of inflammatory arthritis |
| Q52730350 | Mesenchymal stem cells ameliorate experimental arthritis via expression of interleukin-1 receptor antagonist. |
| Q35182959 | Methotrexate intolerance in elderly patients with rheumatoid arthritis: what are the alternatives? |
| Q37280366 | MicroRNA in autoimmunity and autoimmune diseases. |
| Q38497399 | MicroRNAs in autoimmune disease |
| Q38054991 | Mixed treatment comparison of the treatment discontinuations of biologic disease-modifying antirheumatic drugs in adults with rheumatoid arthritis |
| Q36101996 | Modulating P2X7 Receptor Signaling during Rheumatoid Arthritis: New Therapeutic Approaches for Bisphosphonates |
| Q36099553 | Modulating co-stimulation: a rational strategy in the treatment of rheumatoid arthritis? |
| Q35911103 | Molecular targets in immune-mediated diseases: focus on rheumatoid arthritis |
| Q35026014 | Monoclonal antibodies in immune and inflammatory diseases |
| Q34236658 | Monoclonal antibody therapy |
| Q24799750 | Mucosal delivery of anti-inflammatory IL-1Ra by sporulating recombinant bacteria |
| Q30300780 | Myeloid-derived suppressor cells are proinflammatory and regulate collagen-induced arthritis through manipulating Th17 cell differentiation |
| Q57074607 | NLRP3 inflammasome activation contributes to the pathogenesis of rheumatoid arthritis |
| Q39320387 | New Insights into Pericarditis: Mechanisms of Injury and Therapeutic Targets |
| Q38057370 | New biologic-response modifiers in ocular inflammatory disease: beyond anti-TNF treatment. |
| Q33695752 | New targets for anti-inflammatory drugs |
| Q36088346 | New therapies for rheumatoid arthritis |
| Q34990105 | New therapies: plasmapheresis, intravenous immunoglobulin, and monoclonal antibodies |
| Q33758853 | New treatments for rheumatoid arthritis. Available and upcoming slow-acting antirheumatic drugs |
| Q34585191 | Newer immunosuppressive drugs: their potential role in rheumatoid arthritis therapy |
| Q37388213 | Non-tumor necrosis factor-based biologic therapies for rheumatoid arthritis: present, future, and insights into pathogenesis |
| Q46089932 | Novel therapeutic targets along the Th17 pathway |
| Q35040784 | Novel therapies for the treatment of juvenile rheumatoid arthritis (juvenile idiopathic arthritis). |
| Q34096275 | Novel, non-antigen-specific therapeutic approaches to autoimmune/inflammatory diseases |
| Q74622784 | Options for blocking interleukin-1 in patients with rheumatoid arthritis |
| Q47776871 | Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice |
| Q47285878 | Overview of the IL-1 family in innate inflammation and acquired immunity |
| Q74434021 | Pathogenesis of arthritis: recent research progress |
| Q34637331 | Pathogenesis of bone lesions in rheumatoid arthritis |
| Q93017920 | Pathogenic stromal cells as therapeutic targets in joint inflammation |
| Q41828498 | Patients with rheumatoid arthritis in clinical care |
| Q38123032 | Pediatric uveitis: new and future treatments |
| Q39287355 | Periprosthetic osteolysis: characterizing the innate immune response to titanium wear-particles |
| Q38084444 | Pharmacogenetics of disease-modifying antirheumatic drugs in rheumatoid arthritis: towards personalized medicine |
| Q36441438 | Pharmacogenetics of rheumatoid arthritis: Potential targets from susceptibility genes and present therapies |
| Q36644667 | Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody |
| Q53122163 | Pharmacokinetics and Pharmacodynamics of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis. |
| Q58583623 | Pharmacokinetics and Safety of Recombinant Human Interleukin-1 Receptor Antagonist GR007 in Healthy Chinese Subjects |
| Q35198225 | Pharmacological treatment of established rheumatoid arthritis |
| Q38674213 | Pharmacological treatment options for cryopyrin-associated periodic syndromes |
| Q24793076 | Phenotypic characteristics of human monocytes undergoing transendothelial migration |
| Q36260387 | Pigment Epithelium-Derived Factor (PEDF) mediates cartilage matrix loss in an age-dependent manner under inflammatory conditions. |
| Q49915054 | Polymorphisms and expression of inflammasome genes are associated with the development and severity of rheumatoid arthritis in Brazilian patients |
| Q36810295 | Possible therapeutic applications of single-chain antibodies in systemic autoimmune diseases. |
| Q34276030 | Potential biologic agents for treating rheumatoid arthritis |
| Q30863549 | Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases |
| Q38668522 | Preclinical Assessment of Inflammatory Pain |
| Q36243974 | Pro-inflammatory cytokines in rheumatoid arthritis: pathogenetic and therapeutic aspects |
| Q24807339 | Production of interleukin-1 receptor antagonist by human articular chondrocytes. |
| Q24803611 | Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti-TWEAK monoclonal antibodies |
| Q45864537 | Protection against collagen-induced arthritis by intramuscular gene therapy with an expression plasmid for the interleukin-1 receptor antagonist |
| Q28570898 | RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies |
| Q40379845 | Recommendations on therapy using interleukin-1beta-blocking agents |
| Q36617118 | Regulation of osteoclast differentiation and function by interleukin-1. |
| Q74169178 | Relationship of polymorphisms of the Interleukin-1 gene cluster to occurrence and severity of rheumatoid arthritis |
| Q35083436 | Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis |
| Q35174052 | Requirement of the inducible nitric oxide synthase pathway for IL-1-induced osteoclastic bone resorption |
| Q28083593 | Review: basics of drug development in rheumatology |
| Q57349151 | Rheumatoid arthritis |
| Q83860921 | Rheumatoid arthritis |
| Q37988317 | Rheumatoid arthritis and the era of biologic therapy |
| Q34275998 | Rheumatoid arthritis. From bench to bedside |
| Q36160669 | Rheumatoid arthritis: an overview of new and emerging therapies |
| Q34706975 | Rheumatoid arthritis: developing pharmacological therapies |
| Q40090996 | Rilonacept maintains long-term inflammatory remission in patients with deficiency of the IL-1 receptor antagonist |
| Q37484842 | Risk of Herpes Zoster in Individuals on Biologics, Disease-Modifying Antirheumatic Drugs, and/or Corticosteroids for Autoimmune Diseases: A Systematic Review and Meta-Analysis |
| Q33315300 | Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials |
| Q34071325 | Role of interleukin 1 and interleukin 1 receptor antagonist in the mediation of rheumatoid arthritis |
| Q33782333 | Role of tumour necrosis factor alpha in experimental arthritis: separate activity of interleukin 1beta in chronicity and cartilage destruction |
| Q34595156 | Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept |
| Q35194346 | Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritis |
| Q24675209 | Safety of extended treatment with anakinra in patients with rheumatoid arthritis |
| Q58325876 | Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study |
| Q53878659 | Samarium-153-EDTMP in the treatment of refractory rheumatoid arthritis. |
| Q35937819 | Serious infections associated with anticytokine therapies in the rheumatic diseases |
| Q24804764 | Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept |
| Q78754504 | Setting the cytokine trap for autoimmunity |
| Q34779777 | Soluble cytokine receptors in biological therapy |
| Q41981641 | Sonography and subclinical synovitis |
| Q44585210 | Spironolactone inhibits production of proinflammatory cytokines, including tumour necrosis factor-alpha and interferon-gamma, and has potential in the treatment of arthritis |
| Q44301851 | Suppression of human monocyte interleukin-1beta production by ajulemic acid, a nonpsychoactive cannabinoid |
| Q41504272 | Sustained intra-articular delivery of IL-1RA from a thermally-responsive elastin-like polypeptide as a therapy for post-traumatic arthritis |
| Q44700108 | Swertia chirayita mediated modulation of interleukin-1beta, interleukin-6, interleukin-10, interferon-gamma, and tumor necrosis factor-alpha in arthritic mice |
| Q37801555 | Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis |
| Q36452687 | T-cell activation via CD26 and caveolin-1 in rheumatoid synovium |
| Q34895962 | THR0921, a novel peroxisome proliferator-activated receptor gamma agonist, reduces the severity of collagen-induced arthritis |
| Q35880188 | TNF-induced structural joint damage is mediated by IL-1. |
| Q35732863 | Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention |
| Q35144028 | Targeting cytokines in autoimmunity: new approaches, new promise |
| Q37765620 | Targeting inflammation as a therapeutic strategy in accelerated atherosclerosis in rheumatoid arthritis |
| Q86549637 | Targeting innate immunity in type 1 diabetes: strike one |
| Q77838669 | Targeting interleukin-1 in the treatment of rheumatoid arthritis |
| Q41903591 | The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1beta |
| Q37702149 | The NLRP3 inflammasome, a target for therapy in diverse disease states |
| Q26768281 | The Use of IL-1 Receptor Antagonist (Anakinra) in Idiopathic Recurrent Pericarditis: A Narrative Review |
| Q28200818 | The balance between IL-1 and IL-1Ra in disease |
| Q35556360 | The biology of TNF blockade |
| Q73927216 | The challenge of following process, damage, and function in patients with rheumatoid arthritis in clinical care |
| Q45869577 | The contralateral effect conferred by intra-articular adenovirus-mediated gene transfer of viral IL-10 is specific to the immunizing antigen |
| Q39212351 | The development and function of dendritic cell populations and their regulation by miRNAs |
| Q41900249 | The effect of covalently immobilized rhIL-1ra-ELP fusion protein on the inflammatory profile of LPS-stimulated human monocytes |
| Q92124367 | The emerging roles of inflammasome-dependent cytokines in cancer development |
| Q43494262 | The evolving systemic and local biomarker milieu at different stages of disease progression in rat adjuvant-induced arthritis |
| Q34071304 | The final pathogenetic steps in focal bone erosions in rheumatoid arthritis |
| Q34504770 | The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo |
| Q34122715 | The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis |
| Q36617121 | The role of IL-1 and IL-1Ra in joint inflammation and cartilage degradation. |
| Q35540844 | The role of IL-1β in the bone loss during rheumatic diseases. |
| Q35671709 | The role of antibodies in mouse models of rheumatoid arthritis, and relevance to human disease |
| Q45861261 | The role of interleukin-1 receptor antagonist in the prevention and treatment of disease |
| Q35127430 | The role of the interleukin‐6 family of cytokines in inflammatory arthritis and bone turnover |
| Q34654538 | The saga of the discovery of IL-1 and TNF and their specific inhibitors in the pathogenesis and treatment of rheumatoid arthritis |
| Q55449629 | The science of rheumatoid arthritis: a prelude. |
| Q79721915 | The significance of platelet activation in rheumatoid arthritis |
| Q35094697 | The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis |
| Q35859217 | The treatment of rheumatoid arthritis |
| Q34108762 | The treatment of rheumatoid arthritis: a review of recent clinical trials |
| Q36319606 | The use of anakinra in juvenile arthritis |
| Q37552947 | Therapeutic options for rheumatoid arthritis |
| Q35140855 | Therapeutic strategies for rheumatoid arthritis |
| Q34108776 | Therapy of rheumatoid arthritis: new developments and trends |
| Q53614685 | Toll-like receptors: a new target in rheumatoid arthritis? |
| Q37066063 | Toll/Interleukin-1 Receptor Domain Derived from TcpC (TIR-TcpC) Ameliorates Experimental Autoimmune Arthritis by Down-modulating Th17 Cell Response |
| Q37018839 | Transduction of the cytoplasmic domain of CTLA-4 inhibits TcR-specific activation signals and prevents collagen-induced arthritis |
| Q36816872 | Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases |
| Q37636664 | Treating inflammation by blocking interleukin-1 in humans |
| Q26799747 | Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies |
| Q40659435 | Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene |
| Q36793241 | Treatment of osteoarthritis with anakinra |
| Q56060521 | Treatment of rheumatoid arthritis |
| Q33185559 | Treatment of rheumatoid arthritis by interleukin-1 receptor antagonist |
| Q45890242 | Treatment of rheumatoid arthritis with IL-1 inhibitors |
| Q33782376 | Treatment of rheumatoid arthritis with interleukin 1 receptor antagonist |
| Q34967507 | Treatment trials in ankylosing spondylitis: current and future considerations. |
| Q64236406 | Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of Interleukin 1 blockade in Acute Severe Colitis: the IASO trial |
| Q34171367 | Understanding cytokines. Part II: Implications for nursing research and practice |
| Q35553451 | Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003). |
| Q34962946 | Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002). |
| Q36955334 | Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients |
| Q37000165 | Use of biologics in rheumatoid arthritis: current and emerging paradigms of care |
| Q34109021 | Use of biologics in the treatment of childhood rheumatic diseases |
| Q30739084 | Using estimated yearly progression rates to compare radiographic data across recent randomised controlled trials in rheumatoid arthritis. |
| Q39635974 | XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1β-mediated diseases |
| Q53855814 | [Biologicals in treatment of rheumatoid arthritis and other inflammatory arthropathies]. |
| Q80126732 | [Biologicals: a new therapeutic approach for inflammatory diseases] |
| Q44679527 | [Drug therapy of rheumatoid arthritis]. |
| Q81868189 | [Importance of the new biologicals and cytokine antagonists in the treatment of juvenile idiopathic arthritis (JIA)] |
| Q81288165 | [Modern antirheumatic pharmacotherapy. Low molecular weight substances vs. biologicals] |
| Q73370072 | [Rheumatoid arthritis: new molecular and cellular aspects] |
| Q52895477 | [Therapeutic strategies in rheumatoid arthritis]. |
| Q84600283 | [Treatment of rheumatoid arthritis with anakinra: a systematic review] |
| Q74101111 | [Treatment of rheumatoid arthritis] |
Search more.